Is the price fair?
What AVTR's price assumes
Today's price asks for 1.8% free cash flow growth a year; over the last three years Avantor, Inc. delivered −17%, the price is ahead of the record.
0.81
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.7%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +1.8%
Growth the price implies · The price pays for +1.8% free cash flow growth a year for a decade; the business has delivered −17% a year over the last three.
- Price / book
- 0.95
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.95
- EV / EBIToperating margin −4.5%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.35
- Free cash flow, trailing twelve months
- $439M
- Market capitalisation
- $6.54B
- 3-year revenue growth
- −3.7%
- 3-year free cash flow growth
- −17%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #22 of 27 by Smart Score